0RB1.LSE Laboratorio Reig Jofre S.A.
- Market cap
- -
- P/E
- 39.5x
- P/B
- -
- ROE
- -
- Dividend yield
- 0.71%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is 0RB1.LSE undervalued?
Graham numberThe Graham number of Laboratorio Reig Jofre S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Laboratorio Reig Jofre S.A. fundamental analysis
No fundamental analysis for Laboratorio Reig Jofre S.A. yet.
Laboratorio Reig Jofre S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Laboratorio Reig Jofre S.A.
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical devices, cosmetics, parapharmaceuticals, food, and other products. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables and other products; specialty pharmacare products, which include skin, hair, nails, joint …
Full company profileLaboratorio Reig Jofre S.A. financial statements
Laboratorio Reig Jofre S.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 161M | 168M | 180M | 200M | 230M | - | - |
| Gross Profit | 100M | 108M | 118M | 132M | 144M | - | - |
| Operating Income | 13.2M | 9.01M | 10.0M | 6.32M | 9.23M | - | - |
| Net Income | 7.68M | 8.83M | 9.27M | 4.94M | 5.67M | - | - |
| Balance Sheet | |||||||
| Total Assets | 205M | 203M | 220M | 314M | 317M | - | - |
| Total Liabilities | 72.0M | 61.7M | 69.9M | 135M | 133M | - | - |
| Shareholders' Equity | 133M | 142M | 150M | 178M | 185M | - | - |
| Cash & Short-term Investments | 19.3M | 15.0M | 11.0M | 11.1M | 12.4M | - | - |
| Total Debt | 17.2M | 17.1M | 21.1M | 42.5M | 42.8M | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -1.49M | 20.7M | 14.8M | 11.7M | 18.6M | 14.5M | 16.1M |
| Capital Expenditure | 12.2M | 17.0M | 15.9M | 5.85M | 11.8M | 19.2M | 10.9M |
| Ratios | |||||||
| ROE | 5.8% | 6.2% | 6.2% | 2.8% | 3.1% | - | - |
| ROA | 3.7% | 4.3% | 4.2% | 1.6% | 1.8% | - | - |
| Net Profit Margin | 4.8% | 5.3% | 5.1% | 2.5% | 2.5% | - | - |
| Debt to Equity | 0.13x | 0.12x | 0.14x | 0.24x | 0.23x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Laboratorio Reig Jofre S.A. dividends
Laboratorio Reig Jofre S.A. has not paid dividends in the last 9 fiscal years.
Last stock split: 0.05:1 on Sep 22, 2015.
Who owns Laboratorio Reig Jofre S.A.
- Insiders 78.46%
- Institutions 5.85%
- Public & others 15.69%
- Free float 22.0M
Laboratorio Reig Jofre S.A. company profile
- Company name
- Laboratorio Reig Jofre S.A.
- Ticker
- 0RB1.LSE
- ISIN
- ES0165359029
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 1,512
- Fiscal year end
- December
- Address
- Gran Capita, Street 10, Barcelona, Spain
- Phone
- 34 93 480 67 10
- Website
- reigjofre.com/en
About Laboratorio Reig Jofre S.A.
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical devices, cosmetics, parapharmaceuticals, food, and other products. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables and other products; specialty pharmacare products, which include skin, hair, nails, joint health and pain, and women's health; and food supplements under the Forté Pharma brand. In addition, the company provides CDMO and CMO services; and management and administration services. It sells its products through business partners. The company was founded in 1929 and is headquartered in Barcelona, Spain. Laboratorio Reig Jofre, S.A. operates as a subsidiary of Reig Jofre Investments SL.
Laboratorio Reig Jofre S.A. management
3- Mr. Ignasi Biosca ReigCEO & Executive Director
- Ms. Inma Santa-PauDirector of Communication & Investor Relations
- Mr. Inaki Frias InchaustiNon-Director Secretary